- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT01632891
Comparing PI-Based to a nNRTI-based ART for Clearance of Plasmodium Falciparum Parasitemia in HIV-Infected
An Open-Label, Proof of Concept, Randomized Trial Comparing a LPV/r-Based to an nNRTI-Based Antiretroviral Therapy Regimen for Clearance of Plasmodium Falciparum Subclinical Parasitemia in HIV-infected Adults With CD4+ Counts >200 and <500 Cells/mm^3
Descripción general del estudio
Estado
Condiciones
Descripción detallada
A5297 was a Phase I/II, open-label, proof of concept, two-step, two-arm, randomized controlled clinical trial (RCT) to test the superiority of lopinavir/ritonavir (LPV/r)-based antiretroviral therapy (ART) to non-nucleoside reverse transcriptase (nNRTI)-based ART for clearance of Plasmodium falciparum (Pf) subclinical parasitemia (SCP).
The study consisted of two steps. At study Step 1 entry, participants were randomized 1:1 to either LPV/r-based ART or nNRTI-based ART for 15 days. In study Step 2, all participants received nNRTI-based ART and TMP/SMX prophylaxis for 15 days. The total study duration was 30 days.
Study visits occurred every 3 days in Step 1, and every 5 days in Step 2. At each study visit, 2 samples were taken for measurement of parasite density, except day 15 and day 30 at which 3 samples were taken.
Adverse events which occurred after randomization were also recorded. Signs/symptoms and diagnoses were evaluated at each visit, while safety labs (including Hemoglobin, hematocrit, white blood cell count (WBC), differential WBC, platelet count, and absolute neutrophil count (ANC), glucose, electrolytes (sodium, potassium, chloride, bicarbonate), total bilirubin, AST (SGOT), ALT (SGPT), albumin, alkaline phosphatase, and creatinine) were taken at day 15 and day 30, or if indicated at other study visits.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Eldoret, Kenia, 30100
- AMPATH at Moi Univ. Teaching Hosp. Eldoret CRS (12601)
-
Kericho, Kenia, 20200
- Walter Reed Project - Kenya Med. Research Institute Kericho CRS (12501)
-
Kisumu, Kenia, 40100
- Kisumu Crs (31460)
-
-
-
-
-
Blantyre, Malaui
- College of Med. JHU CRS (30301)
-
-
-
-
-
Kampala, Uganda
- Joint Clinical Research Centre (JCRC) (12401)
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- HIV-1 infection
- CD4+ count > 200 and < 500 cells/mm^3 obtained within 30 days prior to study entry at a DAIDS-approved laboratory.
Pf SCP confirmed in a laboratory approved to conduct parasitemia microscopy. Note: Pf SCP defined as meeting all three of the following criteria within 72 hours prior to study entry:
- Microscopy confirmed parasitemia (see section 6.3.6 and the A5297 Manual of Procedures [MOPS])
- An oral temperature < 37.5°C.
The absence of Grade 2 or greater signs or symptoms thought to be related to clinical malaria including:
- headache
- malaise or fatigue
- abdominal discomfort
- muscle or joint pain
- fever
- chills
- perspiration
- anorexia
- vomiting
- other signs or symptoms thought to be related to clinical malaria
- Certain laboratory values obtained within 14 days prior to study entry, as detailed in section 4.1.4 of the protocol.
- Hepatitis B surface antigen (HBsAg) negative within 30 days prior to entry.
- Female study volunteers of reproductive potential have a negative serum or urine pregnancy test performed within 72 hours prior to entry.
- All study volunteers agree not to participate in a conception process (eg, active attempt to become pregnant or to impregnate, sperm donation, in vitro fertilization) for study duration. If participating in sexual activity that could lead to pregnancy, must agree to use two reliable forms of contraceptive simultaneously while receiving protocol-specified medications. One form of contraceptive must be a barrier method if a participant receives EFV. Participants must agree to continue the use of two contraceptives for 6 months after stopping EFV and 6 weeks after stopping all other protocol-specified medications.
- Study volunteers who are not of reproductive potential are eligible without requiring the use of a contraceptive.
- Ability and willingness of participant or legal guardian/representative to provide informed consent.
- Willing and able to return to the clinic twice to three times a day for study visits.
Exclusion Criteria:
Step 1: Exclusion Criteria
- Previous history or current use of ART.
- Single dose NVP or dual therapies used for Prevention of mother-to-child transmission (PMTCT) within 2 years prior to entry.
- Use of any medication with antimalarial activity, including TMP/SMX (see list of prohibited medications in the A5297 Manual of Procedures (MOPS)), within 14 days prior to study entry.
- Confirmed or clinically suspected OIs (including but not limited to tuberculosis, clinical malaria, PCP), or other pulmonary or gastrointestinal infections for which potential participants did not complete treatment more than 30 days prior to enrollment or have signs and symptoms during screening.
- Breastfeeding.
- Known allergy/sensitivity or any hypersensitivity to components of study drugs or their formulation.
- Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
- Serious illness requiring systemic treatment and/or hospitalization within 30 days prior to entry.
- Results suggestive of active pulmonary disease from a chest x-ray performed within 30 days prior to study entry.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: LPV/r-based ART
Participants were prescribed to LPV/r-based antiretroviral therapy (ART) for 15 days, which includes lopinavir/ritonavir plus emtricitabine/tenofovir disoproxil fumarate; followed by an nNRTI-based ART, which includes efavirenz, nevirapine, plus emtricitabine/tenofovir disoproxil fumarate, and Trimethoprim/sulfamethoxazole prophylaxis to take from day 16 through day 30.
|
Participants received two 200 mg/50 mg tablets of lopinavir/ritonavir orally twice daily.
Otros nombres:
Participants received one 200 mg/300 mg tablet of Emtricitabine/tenofovir disoproxil fumarate orally once daily.
Otros nombres:
Participants received one 600 mg tablet of efavirenz orally once daily.
Otros nombres:
If unable to take efavirenz, participants received on 200 mg tablet of nevirapine orally once daily.
Otros nombres:
Participants received one 160 mg/800 mg tablet of trimethoprim/sulfamethoxazole orally once daily.
Otros nombres:
|
Experimental: nNRTI-based ART
Participants were prescribed to nNRTI-based ART for 15 days, which includes efavirenz, nevirapine, plus emtricitabine/tenofovir disoproxil fumarate, followed by an nNRTI-based ART and Trimethoprim/sulfamethoxazole prophylaxis to take from day 16 through day 30.
|
Participants received one 200 mg/300 mg tablet of Emtricitabine/tenofovir disoproxil fumarate orally once daily.
Otros nombres:
Participants received one 600 mg tablet of efavirenz orally once daily.
Otros nombres:
If unable to take efavirenz, participants received on 200 mg tablet of nevirapine orally once daily.
Otros nombres:
Participants received one 160 mg/800 mg tablet of trimethoprim/sulfamethoxazole orally once daily.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Proportion of Participants With Plasmodium Falciparum (Pf) Subclinical Parasitemia (SCP) Clearance
Periodo de tiempo: Day 15 (3 samples collected, separated by at least 5 hours and all three collected within 24-hours)
|
Pf SCP clearance defined by polymerase chain reaction (PCR) < 10 parasites/µL on three consecutive occasions within a 24-hour period. If a participant had missing data on day 15, they were considered as not having clearance. |
Day 15 (3 samples collected, separated by at least 5 hours and all three collected within 24-hours)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Time to First Pf SCP Clearance
Periodo de tiempo: From study entry up to day 30
|
Time to clearance is defined by time to first measurement with PCR < 10 parasites/µL, and is evaluated as the point estimate and 95% CI for the day when 50% of participants cleared parasite.
|
From study entry up to day 30
|
Log10(Pf Parasite Density)
Periodo de tiempo: Entry, days 3, 6, 9, 12, 15, 20, 25, 30
|
Pf parasite density was determined by PCR.
If parasite density equals 0, the value is set to 0.01 before log10 transformation.
The value 0.01 was chosen based on the smallest observed parasite density value of 0.017.
|
Entry, days 3, 6, 9, 12, 15, 20, 25, 30
|
Change in log10(Pf Parasite Density) From Entry to Day 30
Periodo de tiempo: Entry, Day 30
|
Change is evaluated as log10(Pf parasite density) at day 30 minus log10(Pf parasite density) at entry. Change is evaluated in four groups:
|
Entry, Day 30
|
Number of Participants With Uncomplicated Clinical Malaria
Periodo de tiempo: From study entry to day 30
|
Uncomplicated clinical malaria is defined as the presence of non-severe fever/symptoms and parasitemia without organ complication.
|
From study entry to day 30
|
Number of Participants With Detectable Pf Gametocyte Density
Periodo de tiempo: Entry, days 3, 6, 9, 12, 15, 20, 25, 30
|
Number of participants with detectable Pf gametocyte density as determined by PCR.
Due to the large number of undetectable results, this outcome was measured as dichotomous.
|
Entry, days 3, 6, 9, 12, 15, 20, 25, 30
|
Change in log10(Pf Gametocyte Density) From Entry to Day 30
Periodo de tiempo: Entry, Day 30
|
Change in log10(Pf gametocyte density) as evaluated using a Hodges-Lehmann estimate from entry to day 30 is evaluated in two groups:
Analysis was not conducted in either group with clearance at day 15 due to the small sample size and high number of undetectable samples in both clearance groups at entry and day 30. |
Entry, Day 30
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Silla de estudio: Johnstone Kumwenda, FRCP, College of Medicine-Johns Hopkins Project
- Silla de estudio: Douglas Shaffer, MD, MHS, Kenya Medical Research Institute/Walter Reed Project
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Procesos Patológicos
- Infecciones
- Síndrome de Respuesta Inflamatoria Sistémica
- Inflamación
- Septicemia
- Enfermedades parasitarias
- Parasitemia
- Mecanismos moleculares de acción farmacológica
- Agentes antiinfecciosos
- Agentes Antivirales
- Inhibidores de la transcriptasa inversa
- Inhibidores de la síntesis de ácidos nucleicos
- Inhibidores de enzimas
- Agentes Anti-VIH
- Agentes antirretrovirales
- Inhibidores de la proteasa
- Inhibidores del citocromo P-450 CYP3A
- Inhibidores de enzimas del citocromo P-450
- Inductores de enzimas de citocromo P-450
- Agentes antiprotozoarios
- Agentes antiparasitarios
- Inductores de citocromo P-450 CYP3A
- Inhibidores de la proteasa del VIH
- Inhibidores de la proteasa viral
- Antipalúdicos
- Antagonistas del ácido fólico
- Inductores de citocromo P-450 CYP2B6
- Inhibidores del citocromo P-450 CYP2C9
- Agentes contra la discinesia
- Agentes Antiinfecciosos Urinarios
- Agentes renales
- Inhibidores del citocromo P-450 CYP2C19
- Inhibidores del citocromo P-450 CYP2C8
- Tenofovir
- Emtricitabina
- Nevirapina
- Ritonavir
- Lopinavir
- Combinación de fármacos de emtricitabina, tenofovir disoproxil fumarato
- Efavirenz
- Trimetoprima
- Sulfametoxazol
Otros números de identificación del estudio
- ACTG A5297
- 1U01AI068636 (Subvención/contrato del NIH de EE. UU.)
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Infección por VIH-1
-
Icahn School of Medicine at Mount SinaiIRRASReclutamientoHemorragia Intraventricular (HIV)Estados Unidos
-
Oxford Brookes UniversityUniversity of OxfordTerminadoActividad física | Salud Mental Bienestar 1 | Función Cognitiva 1, Social | Academic Attainment | Fitness TestingReino Unido
-
Merck Sharp & Dohme LLCReclutamientoCáncer de pulmón de células no pequeñas | Tumores sólidos | Muerte celular programada-1 (PD1, PD-1) | Ligando 1 de muerte celular programada 1 (PDL1, PD-L1) | Ligando 2 de muerte celular programada 1 (PDL2, PD-L2)Japón
-
Rambam Health Care CampusIsrael Science FoundationTerminado
-
Alvotech Swiss AGTerminado
-
PfizerTerminado
-
SanionaTerminado
-
Calliditas Therapeutics ABEurofins Optimed; York Bioanalytical SolutionTerminado
-
Calliditas Therapeutics ABTerminado
-
JKT Biopharma Co., Ltd.Reclutamiento
Ensayos clínicos sobre Lopinavir/ritonavir
-
Drugs for Neglected DiseasesUniversity of Cape Town; Medecins Sans Frontieres, Netherlands; UBS Optimus Foundation y otros colaboradoresTerminadoSíndrome de inmunodeficiencia adquirida | TuberculosisSudáfrica
-
Institut National de la Santé Et de la Recherche...FUJIFILM Toyama Chemical Co., Ltd.ReclutamientoEnfermedad infecciosa | FarmacologíaFrancia
-
AbbottTerminado
-
Fundacion SEIMC-GESIDAAbbottTerminadoInfecciones por VIH | Infección por VIH | LipodistrofiaEspaña
-
University College, LondonLifeArcTerminado
-
University of California, San DiegoAbbottTerminadoInfección por VIHEstados Unidos
-
Fundacion SEIMC-GESIDAAbbottTerminadoInfecciones por VIH | Coinfección VIH/VHCEspaña
-
Soroka University Medical CenterDesconocido
-
Germans Trias i Pujol HospitalTerminado